NCT03770936 Effect of Some Drugs on Liver Fibrosis
| NCT ID | NCT03770936 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sherief Abd-Elsalam |
| Condition | Liver Fibroses |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2018-10-01 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 45 participants in total. It began in 2018-10-01 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Effect of Some Drugs on Liver Fibrosis
Eligibility Criteria
Inclusion Criteria: * chronic hepatitis C Exclusion Criteria: * Acute hepatitis * Thalassemia
Contact & Investigator
Gamal El-azab, Prof
PRINCIPAL INVESTIGATOR
Clinical pharmacy Department- Tanta University
Frequently Asked Questions
Who can join the NCT03770936 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Liver Fibroses. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03770936 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 45 participants.
Is NCT03770936 currently recruiting?
Yes, NCT03770936 is actively recruiting participants. Contact the research team at sheriefabdelsalam@yahoo.com for enrollment information.
Where is the NCT03770936 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT03770936 clinical trial?
NCT03770936 is sponsored by Sherief Abd-Elsalam. The principal investigator is Gamal El-azab, Prof at Clinical pharmacy Department- Tanta University. The trial plans to enroll 45 participants.